Cargando…

Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing

Cystic fibrosis is a hereditary disease mainly caused by the deletion of the Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. Cystic fibrosis remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fossa, Paola, Uggeri, Matteo, Orro, Alessandro, Urbinati, Chiara, Rondina, Alessandro, Milanesi, Maria, Pedemonte, Nicoletta, Pesce, Emanuela, Padoan, Rita, Ford, Robert C., Meng, Xin, Rusnati, Marco, D’Ursi, Pasqualina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602983/ https://www.ncbi.nlm.nih.gov/pubmed/36293130 http://dx.doi.org/10.3390/ijms232012274

Ejemplares similares

Recent Strategic Advances in CFTR Drug Discovery: An Overview
por: Rusnati, Marco, et al.
Publicado: (2020)

Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications
por: Bugatti, Antonella, et al.
Publicado: (2019)

An Update on CFTR Drug Discovery: Opportunities and Challenges
por: D’Ursi, Pasqualina, et al.
Publicado: (2022)

A Boron Delivery Antibody (BDA) with Boronated Specific Residues: New Perspectives in Boron Neutron Capture Therapy from an In Silico Investigation
por: Rondina, Alessandro, et al.
Publicado: (2021)

Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance
por: Rusnati, Marco, et al.
Publicado: (2018)

HIV-1 Tat and Heparan Sulfate Proteoglycans Orchestrate the Setup of in Cis and in Trans Cell-Surface Interactions Functional to Lymphocyte Trans-Endothelial Migration
por: Urbinati, Chiara, et al.
Publicado: (2021)

Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics
por: D'Ursi, Pasqualina, et al.
Publicado: (2016)

A Bittersweet Computational Journey among Glycosaminoglycans
por: Paiardi, Giulia, et al.
Publicado: (2021)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Modelling the interaction of steroid receptors with endocrine disrupting chemicals
por: D'Ursi, Pasqualina, et al.
Publicado: (2005)

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020)

New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach
por: Righetti, Giada, et al.
Publicado: (2020)

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
por: Rubin, Jaime L., et al.
Publicado: (2019)

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium
por: Braccia, Clarissa, et al.
Publicado: (2022)

Genome-based analysis for the identification of genes involved in o-xylene degradation in Rhodococcus opacus R7
por: Di Canito, Alessandra, et al.
Publicado: (2018)

Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators
por: Sabbadini, Roberto, et al.
Publicado: (2021)

Germline NUP98 Variants in Two Siblings with a Rothmund–Thomson-Like Spectrum: Protein Functional Changes Predicted by Molecular Modeling
por: Colombo, Elisa Adele, et al.
Publicado: (2023)

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
por: Capurro, Valeria, et al.
Publicado: (2021)

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
por: Pohl, Kerstin, et al.
Publicado: (2018)

Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin
por: Rusnati, Marco, et al.
Publicado: (2021)

Correction: Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin
por: Rusnati, Marco, et al.
Publicado: (2021)

Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
por: Armirotti, Andrea, et al.
Publicado: (2019)

Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
por: Parodi, Alice, et al.
Publicado: (2022)

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR
por: Rayment, Jonathan H., et al.
Publicado: (2022)

In silico saturation mutagenesis and docking screening for the analysis of protein-ligand interaction: the Endothelial Protein C Receptor case study
por: Chiappori, Federica, et al.
Publicado: (2009)

Production of CFTR-ΔF508 Rabbits
por: Yang, Dongshan, et al.
Publicado: (2021)

Genome and Phenotype Microarray Analyses of Rhodococcus sp. BCP1 and Rhodococcus opacus R7: Genetic Determinants and Metabolic Abilities with Environmental Relevance
por: Orro, Alessandro, et al.
Publicado: (2015)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)

Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin
por: Caccuri, Francesca, et al.
Publicado: (2021)

Recovery of ΔF508-CFTR Function by Citrate
por: Borkenhagen, Beatrice, et al.
Publicado: (2022)

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial
por: Stahl, Mirjam, et al.
Publicado: (2023)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
por: Yaacoby-Bianu, Karin, et al.
Publicado: (2022)

Defective Fluid Secretion from Submucosal Glands of Nasal Turbinates from CFTR(-/-) and CFTR(ΔF508/ΔF508) Pigs
por: Cho, Hyung-Ju, et al.
Publicado: (2011)

Characterization of Nasal Potential Difference in cftr Knockout and F508del-CFTR Mice
por: Saussereau, Emilie Lyne, et al.
Publicado: (2013)

Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
por: Saint-Criq, Vinciane, et al.
Publicado: (2021)

ProCMD: a database and 3D web resource for protein C mutants
por: D'Ursi, Pasqualina, et al.
Publicado: (2007)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Spectral Analysis on Cuba-Lumacaftor: Cubane as Benzene Bioisosteres of Lumacaftor
por: Wang, Dongdong, et al.
Publicado: (2023)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Pharmacological Correctors of Mutant CFTR Mistrafficking
por: Pedemonte, Nicoletta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0vrfj41t6l55bgb4lk7jqm707j